| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Gypsogenin exhibited significant cytotoxicity against human lung cancer H460 cell line with an IC50 value of 14.02 μM. [1]
It also showed strong cytotoxicity against human gastric cancer SGC-7901 cell line with an IC50 value of 14.36 μM. [1] |
|---|---|
| ln Vivo |
Gypsogenin was tested for antiangiogenic effects using a zebrafish model. All tested compounds (1-6) including gypsogenin showed interesting antiangiogenic activities. [1]
|
| Cell Assay |
The cytotoxic activity of Gypsogenin was evaluated using the MTT method. Human tumour cell lines (lung cancer H460 and gastric cancer SGC-7901) were incubated in RPMI 1640 medium containing 10% foetal bovine serum supplemented with penicillin and streptomycin in a 96-well plate at 37°C for 24 hours. The cells were seeded at an initial density of 1×10^5 cells/mL. Then, the compound was added and cells were cultured for 48 hours at 37°C, with cisplatinum used as a positive control. After incubation, 10 μL of 5 mg/mL MTT solution in phosphate-buffered saline was added to each well, and the cells were incubated for another 4 hours at 37°C in a carbon dioxide incubator. The supernatant was collected from each well, and 200 μL of DMSO was added. The absorbance of the produced formazan was measured at 560 nm using a microplate reader. The inhibition percentage was calculated, and the IC50 value (concentration necessary to inhibit growth to 50% of the control) was calculated by a modified Karber formula. [1]
|
| Animal Protocol |
The antiangiogenic activity of Gypsogenin was assessed using a zebrafish model. The compound was dissolved in 100% DMSO, and then diluted in sterile salt water (5 mM NaCl, 0.17 mM KCl, 0.4 mM CaCl2, 0.16 mM MgSO4) to obtain final solutions of various concentrations in 0.1% DMSO. Aliquots were placed into a 96-well culture plate. Zebrafish embryos at 24 hours post-fertilisation (hpf) were transferred into the 96-well culture plate. PTK787 was used as a positive control. All embryos were incubated at 28.5°C. After 48 hours of treatment, the intersegmental vessels of embryos were visualised with green fluorescent protein labelling and endogenous alkaline phosphatase staining. The antiangiogenic activity was calculated from the inhibition ratio of angiogenesis. [1]
|
| References | |
| Additional Infomation |
Caryophyllinogenin is a saponin with the structure oleanolic-12-en-28-acid, substituted with a β-hydroxyl group at position 3 and a carbonyl group at position 23. It is a pentacyclic triterpenoid compound belonging to the saponin, aldehyde, and monocarboxylic acid classes. Its function is related to oleanolic acid. It is the conjugate acid of caryophyllinogenin (1-). Caryophyllinogenin has been reported to exist in plants of the genus Caryophyllum (such as Silene firma), Gypsophila pacifica, and other organisms with relevant data.
Gypsogenin (compound 4) is a known triterpenoid isolated from the roots of Gypsophila oldhamiana Miq., a plant used in traditional Chinese medicine. Its structure was identified by spectral methods and comparison with literature (Nie et al. 1989). [1] |
| Molecular Formula |
C30H46O4
|
|---|---|
| Molecular Weight |
470.69
|
| Exact Mass |
470.339
|
| CAS # |
639-14-5
|
| PubChem CID |
92825
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
581.1±50.0 °C at 760 mmHg
|
| Flash Point |
319.3±26.6 °C
|
| Vapour Pressure |
0.0±3.7 mmHg at 25°C
|
| Index of Refraction |
1.564
|
| LogP |
7.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
936
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C=O)O
|
| InChi Key |
QMHCWDVPABYZMC-MYPRUECHSA-N
|
| InChi Code |
InChI=1S/C30H46O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,18,20-23,32H,8-17H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(3beta,4alpha)-3-Hydroxy-23-oxoolean-12-en-28-oic acid
|
| Synonyms |
Albsapogenin Astrantiagenin D Gypsophilasapogenin GypsogeninGithagenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~53.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1245 mL | 10.6227 mL | 21.2454 mL | |
| 5 mM | 0.4249 mL | 2.1245 mL | 4.2491 mL | |
| 10 mM | 0.2125 mL | 1.0623 mL | 2.1245 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
